HC Wainwright Expects Higher Earnings for Benitec Biopharma

Benitec Biopharma Inc. (NASDAQ:BNTC - Free Report) - Investment analysts at HC Wainwright lifted their FY2025 earnings per share (EPS) estimates for shares of Benitec Biopharma in a report released on Monday, May 19th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings per share of ($1.33) for the year, up from their previous estimate of ($1.55). HC Wainwright has a "Buy" rating and a $28.00 price objective on the stock. The consensus estimate for Benitec Biopharma's current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Benitec Biopharma's Q4 2025 earnings at ($0.25) EPS.

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The biotechnology company reported ($0.24) EPS for the quarter, topping analysts' consensus estimates of ($0.36) by $0.12.

Separately, JMP Securities reaffirmed a "market outperform" rating and issued a $20.00 price target on shares of Benitec Biopharma in a report on Thursday, May 15th. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $24.71.

Benitec Biopharma Stock Down 0.4%

BNTC stock opened at $13.93 on Wednesday. Benitec Biopharma has a 52-week low of $5.74 and a 52-week high of $16.90. The firm has a market cap of $356.61 million, a P/E ratio of -9.23 and a beta of 0.34. The company's 50-day simple moving average is $13.65 and its 200-day simple moving average is $12.07.

Institutional Investors Weigh In On Benitec Biopharma

Hedge funds have recently modified their holdings of the company. Franklin Resources Inc. grew its stake in shares of Benitec Biopharma by 269.0% in the 4th quarter. Franklin Resources Inc. now owns 2,939,287 shares of the biotechnology company's stock valued at $37,123,000 after buying an additional 2,142,643 shares during the period. Janus Henderson Group PLC raised its position in shares of Benitec Biopharma by 198.5% during the 4th quarter. Janus Henderson Group PLC now owns 2,616,427 shares of the biotechnology company's stock valued at $33,268,000 after buying an additional 1,739,904 shares during the period. Adage Capital Partners GP L.L.C. lifted its holdings in Benitec Biopharma by 134.4% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,972,524 shares of the biotechnology company's stock valued at $24,913,000 after acquiring an additional 1,131,129 shares during the last quarter. Infinitum Asset Management LLC grew its position in Benitec Biopharma by 435.7% in the first quarter. Infinitum Asset Management LLC now owns 1,125,000 shares of the biotechnology company's stock worth $14,636,000 after acquiring an additional 915,000 shares during the period. Finally, Suvretta Capital Management LLC grew its position in Benitec Biopharma by 1.5% in the fourth quarter. Suvretta Capital Management LLC now owns 8,960,009 shares of the biotechnology company's stock worth $113,165,000 after acquiring an additional 130,956 shares during the period. Hedge funds and other institutional investors own 52.19% of the company's stock.

Insider Buying and Selling

In other news, Director Suvretta Capital Management, L acquired 900,000 shares of Benitec Biopharma stock in a transaction that occurred on Wednesday, March 26th. The stock was purchased at an average cost of $13.00 per share, with a total value of $11,700,000.00. Following the purchase, the director now owns 8,793,245 shares in the company, valued at $114,312,185. This trade represents a 11.40% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is currently owned by insiders.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.